Coronavirus Notebook: Australia OKs GSK’s Sotrovimab For COVID-19, Iran Takes SpikoGen Vaccine Into Phase III
Executive Summary
Bavarian Nordic is testing the potential of its ABNCoV2 vaccine as a booster dose for people with previous infection or vaccination. Brazil has received requests from Pfizer/BioNTech and AstraZeneca to trial vaccines as booster doses, and has asked for more immunogenicity data on SinoVac’s CoronaVac.
You may also be interested in...
GMP Deficiencies Lead Brazil To Target Sinovac’s Chinese COVID-19 Vaccine Plant
Having decided to suspend 12 million doses of Sinovac’s coronavirus vaccine, Brazil’s regulatory agency says it will need to make its own on-site assessment of conditions at the Chinese facility that makes the product.
UK Approves Regeneron/Roche MAb Cocktail For COVID-19
The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”
Coronavirus Notebook: WHO Adds More Drugs To Solidarity Trial, COVAX Ups Vaccine Supplies To Africa
The Coalition for Epidemic Preparedness and Innovations is working with China’s ZerunBio to develop prototype and variant vaccine candidates, and Australia believes MSD’s molnupiravir could be a potential treatment for COVID-19. The European Medicines Agency is looking into more possible side effects with two mRNA vaccines.